Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries

Molecular Imaging
|September 25, 2014
PubMed

Insights

Cabozantinib causes bone scans to appear normal by reducing radiotracer uptake in bone, even without tumors. The exact mechanism remains unclear, warranting caution in interpreting these imaging results.

Area of Science:

  • Oncology
  • Radiology
  • Pharmacology

Background:

  • Cabozantinib is a receptor tyrosine kinase inhibitor with clinical activity in various cancers.
  • Rapid resolution of bone scans is a notable observation in patients treated with cabozantinib for bone-metastatic cancers.
  • This phenomenon suggests a potential interference with bone-seeking radiotracer uptake.

Purpose of the Study:

  • To investigate the effect of cabozantinib on radiotracer accumulation in bone remodeling.
  • To explore the underlying molecular mechanisms of cabozantinib-induced bone scan resolution.

Main Methods:

  • Surgically induced bone remodeling in non-tumor-bearing mice.
  • 18F-sodium fluoride (18F-NaF) PET and 99mTc-methylene diphosphonate (99mTc-MDP) SPECT imaging before and after cabozantinib treatment.
  • Administration of selective receptor tyrosine kinase inhibitors (axitinib, crizotinib) to assess their impact on radiotracer uptake.

Main Results:

  • Cabozantinib treatment consistently reduced radiotracer accumulation at sites of bone remodeling.
  • Neither VEGFR inhibitor axitinib nor MET inhibitor crizotinib inhibited 18F-NaF accumulation at bioactive doses.
  • The observed effect occurred in tumor-naïve models.

Conclusions:

  • Cabozantinib significantly reduces radiotracer uptake in remodeling bone, independent of tumor presence.
  • The precise mechanism by which cabozantinib affects radionuclide incorporation into bone remains to be elucidated.
  • Clinical interpretation of bone scan resolution in patients treated with cabozantinib requires careful consideration.

Related Concept Videos